Biogen Exposure Increased with 2028 $150 Calls as Alzheimer’s Pipeline Advances
Patient Opportunity Equity Strategy boosted Biogen exposure by buying 2028 call options at a $150 strike, citing late-stage pipeline assets and an expanding Alzheimer’s franchise. Biogen shares closed at $189.94 on March 4, with a 2.47% one-month gain, 28.9% 52-week return and a $27.9B market cap.
1. Strategy Adds 2028 Call Options
Patient Opportunity Equity Strategy increased its Biogen position by purchasing long-dated call options expiring in 2028 with a $150 strike, signaling strong conviction in the company’s future performance.
2. Long-Term Growth Drivers
The fund cited Biogen’s late-stage clinical pipeline and the broadening Alzheimer’s franchise—driven by blood-based biomarkers and subcutaneous injections—as key catalysts for sustained growth.
3. Recent Share Performance
Biogen shares closed at $189.94 on March 4, posted a 2.47% one-month gain and a 28.9% return over the past year, reflecting investor confidence ahead of upcoming pipeline readouts.
4. Institutional Ownership Trends
Hedge fund holdings in Biogen rose to 68 portfolios at the end of Q4 2025 from 59 in the prior quarter, underscoring growing institutional interest.